Axl receptor axis: A new therapeutic target in lung cancer

Journal of Thoracic Oncology

Volumn 11, Issue 8, 2016, Pages 1357-1362

  Levin, Pavel A ^a   Brekken, Rolf A ^a   Byers, Lauren Averett ^b   Heymach, John V ^b   Gerber, David E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASLAN 002; AXL RECEPTOR; BGB 324; BPI 9016; CABOZANTINIB; CRIZOTINIB; ERLOTINIB; FORETINIB; MGCD 265; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SITRAVATINIB; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR;

3' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; ARTICLE; CHROMOSOME 19; CLINICAL TRIAL (TOPIC); EXON; GENE EXPRESSION REGULATION; HUMAN; LUNG CANCER; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; TRANSLATION REGULATION; ANTAGONISTS AND INHIBITORS; LUNG TUMOR; METABOLISM; PATHOLOGY;

HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84982083046     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.04.015     Document Type: Article

References (36)

1. Subramanian M, Hayes CD, Thome JJ, et al. An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo. J Clin Invest. 2014;124:1296-1308.
2. Cosemans JM, Van Kruchten R, Olieslagers S, et al. Potentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization. J Thromb Haemost. 2010;8: 1797-1808.
3. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol. 2008;8:327-336.
4. Elkabets M, Pazarentzos E, Juric D, et al. AXL mediates resistance to PI3Kalpha inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell. 2015;27: 533-546.
5. Bellosta P, Costa M, Lin DA, Basilico C. The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding. Mol Cell Biol. 1995;15:614-625.
6. Burchert A, Attar EC, McCloskey P, Fridell YW, Liu ET. Determinants for transformation induced by the Axl receptor tyrosine kinase. Oncogene. 1998;16:3177-3187.
7. Cui ZL, Han FF, Peng XH, et al. YES-associated protein 1 promotes adenocarcinoma growth and metastasis through activation of the receptor tyrosine kinase Axl. Int J Immunopathol Pharmacol. 2012;25:989-1001.
8. Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, Allgayer H. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene. 2011;30:2888-2899.
9. Vaughan CA, Singh S, Windle B, et al. Gain-of-function activity of mutant p53 in lung cancer through upregulation of receptor protein tyrosine kinase Axl. Genes Cancer. 2012;3:491-502.
10. Choi YJ, Kim SY, So KS, et al. AUY922 effectively overcomes MET-and AXL-mediated resistance to EGFR-TKI in lung cancer cells. PLoS One. 2015;10:e0119832.
11. Do KT, MacConaill L, Dubuc A, et al. Evaluation of the MET/AXL receptor tyrosine kinase (RTK) inhibitor MGCD265 in a patient with metastatic non-small cell lung cancer (NSCLC) harboring AXL amplification. Paper presented at: 16th World Conference on Lung Cancer. September 6-9, 2015; Denver, CO.
12. Martinelli E, Martini G, Cardone C, et al. AXL is an oncotarget in human colorectal cancer. Oncotarget. 2015;6:23281-23296.
13. Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 2012;22:2109-2119.
14. Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 2014;14: 769-785.
15. Meyer AS, Zweemer AJ, Lauffenburger DA. The AXL Receptor is a sensor of ligand spatial heterogeneity. Cell Syst. 2015;1:25-36.
16. Goruppi S, Ruaro E, Varnum B, Schneider C. Requirement of phosphatidylinositol 3-kinase-dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts. Mol Cell Biol. 1997;17:4442-4453.
17. Fridell YW, Jin Y, Quilliam LA, et al. Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol Cell Biol. 1996;16:135-145.
18. Abu-Thuraia A, Gauthier R, Chidiac R, et al. Axl phosphorylates Elmo scaffold proteins to promote Rac activation and cell invasion. Mol Cell Biol. 2015;35:76-87.
19. O'Bryan JP, Frye RA, Cogswell PC, et al. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991;11:5016-5031.
20. Byers LA, Diao L, Wang J, et al. An epithelialmesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013;19:279-290.
21. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epithelial-tomesenchymal transition and regulates the function of breast cancer stem cells. Oncogene. 2014;33:1316-1324.
22. Gjerdrum C, Tiron C, Hoiby T, et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A. 2010;107:1124-1129.
23. Wu F, Li J, Jang C, Wang J, Xiong J. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma. Int J Clin Exp Pathol. 2014;7:6653-6661.
24. Brand TM, Iida M, Stein AP, et al. AXL mediates resistance to cetuximab therapy. Cancer Res. 2014;74:5152-5164.
25. Brand TM, Iida M, Stein AP, et al. AXL Is a logical molecular target in head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21:2601-2612.
26. Wilson C, Ye X, Pham T, et al. AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. Cancer Res. 2014;74:5878-5890.
27. Li Y, Ye X, Tan C, et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene. 2009;28: 3442-3455.
28. Shieh YS, Lai CY, Kao YR, et al. Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia. 2005;7:1058-1064.
29. Ishikawa M, Sonobe M, Nakayama E, et al. Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients. Ann Surg Oncol. 2013;20(suppl 3):S467-S476.
30. Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012;44:852-860.
31. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3, 75ra26.
32. Paolino M, Choidas A, Wallner S, et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014;507:508-512.
33. Myers SH, Brunton VG, Unciti-Broceta A. AXL inhibitors in cancer: a medicinal chemistry perspective. J Med Chem. 2015;59:3593-3608.
34. Ye X, Li Y, Stawicki S, et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene. 2010;29:5254-5264.
35. Cerchia L, Esposito CL, Camorani S, et al. Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther. 2012;20:2291-2303.
36. Kirane A, Ludwig KF, Sorrelle N, et al. Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis. Cancer Res. 2015;75:3699-3705.